Feb 26, 2026 07:32AM
Feb 26, 2026 07:30AM
Feb 24, 2026 07:30AM
Feb 12, 2026 07:31AM
Feb 12, 2026 07:30AM
Dec 18, 2025 07:30AM
Dec 18, 2025 07:30AM Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
Dec 17, 2025 07:30AM
Dec 17, 2025 07:30AM
Dec 10, 2025 08:30AM
Dec 5, 2025 08:30AM
Dec 5, 2025 08:30AM
Dec 4, 2025 08:30AM
Dec 3, 2025 08:30AM Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Dec 2, 2025 08:30AM
Nov 19, 2025 07:30AM
Nov 19, 2025 07:30AM
Nov 7, 2025 07:30AM
Oct 14, 2025 07:30AM
Oct 14, 2025 07:30AM
Oct 8, 2025 07:00AM Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates
Oct 7, 2025 07:30AM
Oct 7, 2025 07:30AM
Sep 30, 2025 07:30AM
Sep 30, 2025 07:30AM
Sep 29, 2025 04:05PM
Sep 29, 2025 04:05PM
Sep 26, 2025 06:34AM Soligenix prices $7.5 million public offering at $1.35 per share
Sep 26, 2025 06:33AM
Sep 23, 2025 07:30AM
Sep 23, 2025 07:30AM
Sep 4, 2025 07:31AM
Sep 4, 2025 07:30AM
Sep 2, 2025 07:30AM
Aug 18, 2025 07:30AM Soligenix receives FDA orphan drug designation for Behçet's disease
Aug 18, 2025 07:30AM
Aug 14, 2025 07:30AM
Aug 8, 2025 08:30AM
Aug 7, 2025 08:31AM
Aug 7, 2025 08:30AM
Aug 7, 2025 08:30AM
Aug 5, 2025 08:30AM Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Jul 31, 2025 07:30AM
Jul 31, 2025 07:30AM
Jul 31, 2025 07:30AM
Jul 8, 2025 07:30AM
Jul 1, 2025 07:30AM
Jul 1, 2025 07:30AM
Jun 6, 2025 09:37AM Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
May 9, 2025 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All